Additional file 3: of V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients

Summary of repertoire sequencing output and overlapping proportions in end-stage renal disease samples. (DOCX 14 kb

Additional file 2: of V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients

Overlapping read length distribution plot of end-stage renal disease patients. QC, quality control. (DOCX 260 kb

Additional file 7: of V-J combinations of T-cell receptor predict responses to erythropoietin in end-stage renal disease patients

Quantification of T-cell repertoire diversity in end-stage renal disease (ESRD) patients. a The clonotype distribution plots of ESRD patients. The x-axis and y-axis are log10 scaled. The value of 1/D represents the T-cell receptor (TCR) β repertoire diversity. b Comparison of TCR repertoire diversity (log-scaled) between erythropoietin (EPO) responders and EPO resistants (p = 0.642) (DOCX 232 kb

Additional file 1: Table S1. of The association between BDNF Val66Met polymorphism and emotional symptoms after mild traumatic brain injury

The confounding factors for BAI and BDI scores. Figure S1. Correlation between BAI and BDI score in the first week (p-value < 0.001; Adjusted R2 = 0.3101). Figure S2. Correlation between BAI and BDI score in the sixth week (p-value < 0.001; Adjusted R2 = 0.5013). (DOCX 175 kb

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist

BMS-711939 (<b>3</b>) is a potent and selective peroxisome proliferator-activated receptor (PPAR) α agonist, with an EC₅₀ of 4 nM for human PPARα and >1000-fold selectivity vs human PPARγ (EC₅₀ = 4.5 μM) and PPARδ (EC₅₀ > 100 μM) in PPAR-GAL4 transactivation assays. Compound <b>3</b> also demonstrated excellent <i>in vivo</i> efficacy and safety profiles in preclinical studies and thus was chosen for further preclinical evaluation. The synthesis, structure–activity relationship (SAR) studies, and <i>in vivo</i> pharmacology of <b>3</b> in preclinical animal models as well as its ADME profile are described